Divi's Labs profit jumps 64% as margins expand

Divi's Laboratories Limited (NSE: DIVISLAB) reported a strong Q2 FY27 performance, with consolidated revenue from operations increasing 35.4% YoY to ₹3,676 crore. Net profit surged 63.6% to ₹1,127 crore, compared with ₹689 crore in the corresponding quarter last year. Key Highlights • Revenue increased 35.4% YoY to ₹3,676 crore. • Net profit rose 63.6% to ₹1,127 crore. • Operating profit increased approximately 61% YoY. • Operating margin expanded to 42.6% from 32.7% a year earlier. • Profit before tax increased to ₹1,505 crore from ₹912 crore. • Revenue grew approximately 19.4% sequentially compared with Q1 FY27. • Earnings per share increased to ₹42.49 from ₹25.97. My View Divi's Laboratories delivered an impressive quarter, with both revenue growth and profitability improving significantly. The expansion in operating margin is particularly encouraging. It indicates that profit growth was supported not only by higher sales but also by improved operating performance. However, pharmaceutical companies remain exposed to regulatory requirements, customer concentration, pricing pressure and changes in global demand. The key question is whether the current margin improvement can be sustained over the coming quarters. What I'm Watching Next I will monitor API and custom synthesis demand, capacity utilisation, operating margins and the sustainability of growth in international markets. The company's ability to maintain high margins while expanding its manufacturing capabilities will be important. Stance: Positive on revenue growth, profitability and margin expansion, while remaining watchful of sustainability and valuation. Disclosure: I do not have any holding or position in the stock mentioned above. DIVISLAB